Overview

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Status:
Completed
Trial end date:
1992-01-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
NICHD Neonatal Research Network
Treatments:
Beractant
Pulmonary Surfactants
Criteria
Inclusion Criteria:

- Newborn infants weighing 501 to 1500 gm with respiratory distress syndrome were
receiving assisted ventilation with 30% oxygen or more

Exclusion Criteria:

- Less than 6 hours of age